Bavarian Nordic
Language: en / da SitemapDownloadsContact
 Search:
  • Core Competences
  • Pipeline
  • Business Development
  • Investor
  • Join Us
  • About Us
  • Cancer
  • Biodefence
  • Infectious Diseases

Investor

  • News
  • Media Clippings
    • Share Information
    • Financials
    • Calendar
    • General Meetings
    • Presentations
    • Investor Services
    • Contact

    Media Clippings

    Latest market and company news in the media:

    • Senators Ask Why Medicare Is Reviewing Provenge
    • Counter-Bioterrorism Reform Plan Looks Promising, Experts Say
    • Feds to Devote New Funds to Fight Flu, Bioterror
    • Gains in Bioscience Cause Terror Fears
    • Dendreon's $93,000 Cancer Drug Price Must Be Paid by U.S., Doctors Say
    • Provenge Cancer Vaccine: Can You Put a Price on Delaying Death?
    • Smallpox vaccine may offer protection against HIV infection
    • The Launch and Uptake of Nine Emerging Therapies Will Drive the Prostate Cancer Drug Market to More Than Double to $8.4 Billion in 2019
    • First Smallpox Vaccine for Special Populations Delivered Under Project BioShield
    • Next-generation smallpox vaccine being stockpiled
    • White House Aims to Boost U.S. Biosecurity
    • SLU Studies New Smallpox Vaccine
    • U.S. Biodefense Spending to Increase
    • Aetna Confirms It Will Cover Provenge
    • New prostate cancer vaccine
    • Vaccine Injection Targeted in Building a Better ‘Bull’s-Eye’ to Fight Prostate Cancer
    • U.S. stockpile receives smallpox vaccine
    • Home